Management of Ulcerative Colitis Flare

Disease Severity Assessment and Treatment

The American Gastroenterological Association recommends assessing flare severity using clinical symptoms and biomarkers, with moderate-to-severe symptoms warranting immediate corticosteroid therapy 2
For patients with mild-to-moderate symptoms and elevated biomarkers, treatment adjustment is necessary to achieve remission 3
Severe symptoms with elevated biomarkers rule in active inflammation and justify treatment escalation without routine endoscopy 3

For mild-to-moderate active UC, the European Crohn’s and Colitis Organisation recommends oral 5-ASA at doses ≥2g/day as first-line therapy 1
For left-sided disease or proctitis, adding topical 5-ASA is recommended for superior efficacy 1
Oral corticosteroids (prednisone 40-60mg daily) are recommended as second-line therapy to induce remission in patients who fail 5-ASA 1, 2
For moderate-to-severe active UC, oral corticosteroids are recommended as primary induction therapy 1, 2
Anti-TNF therapy (infliximab, adalimumab, or golimumab) combined with thiopurine (azathioprine) or methotrexate is recommended for corticosteroid-refractory or dependent patients 1, 2, 4, 5

The American Gastroenterological Association recommends never using corticosteroids for maintenance therapy due to ineffectiveness and significant adverse effects 1, 4, 2
Corticosteroid-dependent patients require escalation to anti-TNF therapy or vedolizumab 4, 2
Combination therapy with anti-TNF agents and thiopurine or methotrexate reduces immunogenicity and improves sustained clinical response (HR 3.98, 95% CI 1.73-9.14) 5, 6

The European Crohn’s and Colitis Organisation recommends continuing the same agents used for induction (except corticosteroids) to maintain remission 8, 7, 9
For anti-TNF responders, continuing anti-TNF therapy indefinitely is recommended to maintain remission 4, 2, 5
Long-term 5-ASA maintenance may reduce colorectal cancer risk 5